Solid Biosciences Inc.

NasdaqGS:SLDB Stock Report

Market Cap: US$459.7m

Solid Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bo Cumbo

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage12.49%
CEO tenure3yrs
CEO ownership0.1%
Management average tenure3yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Oct 23
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 09
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Apr 08

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Jan 21

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Nov 16
Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Jul 26
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Buy Solid Biosciences: Unpacking Its Main Value Driver

Apr 10

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Jan 17

Solid Biosciences to acquire gene therapy company AavantiBio

Sep 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30
Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28
Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28
Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13
We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

CEO Compensation Analysis

How has Bo Cumbo's remuneration changed compared to Solid Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$167m

Jun 30 2025n/an/a

-US$154m

Mar 31 2025n/an/a

-US$140m

Dec 31 2024US$5mUS$608k

-US$125m

Sep 30 2024n/an/a

-US$102m

Jun 30 2024n/an/a

-US$91m

Mar 31 2024n/an/a

-US$90m

Dec 31 2023US$919kUS$585k

-US$96m

Sep 30 2023n/an/a

-US$91m

Jun 30 2023n/an/a

-US$90m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$4mUS$46k

-US$86m

Compensation vs Market: Bo's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD2.30M).

Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.

CEO

Bo Cumbo (54 yo)

3yrs
Tenure
US$4,869,909
Compensation

Mr. Alexander G. Cumbo, also known as Bo, has been the Director at Vor Biopharma Inc. since July 16, 2025. He is an Independent Director of Climb Bio, Inc. from April 2025. He serves as President, Chief Ex...

Leadership Team

NamePositionTenureCompensationOwnership
Ian Smith
Executive Chair5.7yrsUS$449.16k0.16%
$ 747.5k
Alexander Cumbo
President3yrsUS$4.87m0.10%
$ 480.2k
Ilan Ganot
Co-founder12.9yrsUS$505.35k0.17%
$ 764.9k
David Howton
COO & Secretary3yrsUS$2.56m0.042%
$ 194.2k
Gabriel Brooks
Chief Medical Officer2.2yrsUS$2.07m0.043%
$ 199.5k
Annie Ganot
Co-Founder & VP of Patient Advocacyno datano datano data
Kevin Tan
CFO & Treasurer2.9yrsUS$1.36m0.041%
$ 190.3k
Paul Herzich
Chief Technology Officer3yrsno data0.034%
$ 157.1k
Nicole Anderson
Director of Investor Relations & Corporate Communicationsno datano datano data
Allison Bogosian
Senior Vice President of Human Resources3.9yrsno datano data
Jessie Hanrahan
Chief Regulatory & Preclinical Operations Officer3yrsno data0.034%
$ 157.3k
Shuli Kulak
Head of Corporate Strategy & Business Development2.3yrsno datano data
3.0yrs
Average Tenure
50yo
Average Age

Experienced Management: SLDB's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ian Smith
Executive Chair5.7yrsUS$449.16k0.16%
$ 747.5k
Alexander Cumbo
President3yrsUS$4.87m0.10%
$ 480.2k
Ilan Ganot
Co-founder12.9yrsUS$505.35k0.17%
$ 764.9k
Jeffrey Bluestone
Member of Scientific Advisory Boardno datano datano data
Laurence Turka
Member of Scientific Advisory Boardno datano datano data
Jeffrey Chamberlain
Chairman of Scientific Advisory Board7.9yrsno datano data
Adam Stone
Lead Independent Director10.1yrsUS$279.70k0%
$ 0
Lynne Sullivan
Independent Director10.1yrsUS$283.20k0%
$ 0
Carrie Miceli
Member of Scientific Advisory Boardno datano datano data
Ronald Cohn
Member of Scientific Advisory Boardno datano datano data
Dongsheng Duan
Member of Scientific Advisory Boardno datano datano data
Georgia Keresty
Independent Director4.8yrsUS$273.45k0%
$ 0
7.9yrs
Average Tenure
59yo
Average Age

Experienced Board: SLDB's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 07:44
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Solid Biosciences Inc. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Timothy ChiangBTIG
Kristen KluskaCantor Fitzgerald & Co.